Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of diabetes on sugammadex reversal of rocuronium-induced deep neuromuscular blockade
ChiCTR2100046634Phase 4Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex in type 2 diabetes mellitus (T2DM) and gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Time from administration of sugammadex to recovery of train-of-four ratio to ≥0.9. Started Jun 2021; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
type 2 diabetes mellitus (T2DM)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR2100046634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046634.